GH Research (NASDAQ:GHRS) Given New $28.00 Price Target at Canaccord Genuity Group

GH Research (NASDAQ:GHRS) had its price objective decreased by research analysts at Canaccord Genuity Group from $31.00 to $28.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target suggests a potential upside of 191.36% from the stock’s current price.

Several other equities research analysts also recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of GH Research in a report on Thursday, September 5th. JMP Securities restated a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a report on Wednesday, September 4th.

GH Research Stock Performance

Shares of NASDAQ:GHRS opened at $9.61 on Monday. The company has a market cap of $499.99 million, a P/E ratio of -12.16 and a beta of 0.74. GH Research has a one year low of $5.05 and a one year high of $14.99. The business’s 50-day simple moving average is $7.82 and its 200 day simple moving average is $10.33.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. Analysts predict that GH Research will post -0.85 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP lifted its position in GH Research PLC (NASDAQ:GHRS) by 19.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,966,726 shares of the company’s stock after acquiring an additional 656,163 shares during the quarter. GH Research accounts for approximately 16.7% of Lynx1 Capital Management LP’s holdings, making the stock its 3rd largest position. Lynx1 Capital Management LP owned 7.62% of GH Research worth $46,252,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).